Lotus

hero-background
logologo
logologo
At Lotus, every dose matters. As a Top 20 Global Specialty Pharmaceutical Company, we deliver trusted, high-quality medicines with greater scale, speed, and reach—bringing better care to more people, everywhere.
At Lotus, every dose matters. As a Top 20 Global Specialty Pharmaceutical Company, we deliver trusted, high-quality medicines with greater scale, speed, and reach—bringing better care to more people, everywhere.

Our Company

Lotus Pharmaceutical (stock code: 1795 TT) is a fast-growing specialty pharmaceutical company headquartered in Taiwan. As one of the largest specialty pharma companies in the region, Lotus focuses on developing, manufacturing, in-licensing and commercialising high-quality medicines across 90+ markets in the world. With best-in-class R&D capabilities and strong manufacturing platforms, Lotus combines innovation and efficiency under one integrated network. Through its hybrid portfolio strategy — balancing in-house R&D with strategic business development — Lotus continues to build an optimised, sustainable pipeline of specialty and complex products.
Section ImageSection ImageSection Image

Advancing Medicine with Every Dose

From patients to healthcare providers, our medicines deliver quality, access, and impact across therapeutic areas and global markets.

GENERICS
BRANDS
505(b)(2)
BIOSIMILARS
NCEs

We offer a broad range of generics with a strong emphasis on oncology and immunology. With a proven track record in therapies such as Lenalidomide, Gefitinib, and Vinorelbine softgel capsules, we are dedicated to advancing complex generics that support patient wellness and improve lives.

Our Pipeline:
Innovating for a Healthier Tomorrow

Lotus builds an optimised and sustainable pipeline through its hybrid portfolio strategy through developing high-barrier medicines in-house and forging strategic partnerships — we focus on expanding access to essential therapies and improving patient health globally.

Commercial Products
250+
Commercial Products
R&D Pipelines
80+
R&D Pipelines
Global Partnerships
100+
Global Partnerships
Licensing Deals Signed
265+
Licensing Deals Signed

Latest News

Explore our latest articles, in-depth reports, and thought leadership pieces
Main Article Image
BusinessFeb 24, 2026

Lotus Pharmaceutical Announces 505(b)(2) NDA Filing for LP757 (Cabozantinib)

BusinessFeb 24, 2026

Lotus Pharmaceutical Announces 505(b)(2) NDA Filing for LP757 (Cabozantinib)

articleBtnImg
Business

Solaxa and Alvogen Enter into License Agreement for the Development and Commercialization of SLX-100

Solaxa and Alvogen Enter into License Agreement for the Development and Commercialization of SLX-100
Business

Lotus Pharmaceutical becomes commercialization partner for Formycon's Keytruda® biosimilar candidate FYB206 across major parts of the Asia-Pacific Region

Lotus Pharmaceutical becomes commercialization partner for Formycon's Keytruda® biosimilar candidate FYB206 across major parts of the Asia-Pacific Region
Business

Lotus Pharmaceutical Advances Vietnam Drug Portfolio Acquisition

Lotus Pharmaceutical Advances Vietnam Drug Portfolio Acquisition
Business

Lotus Pharmaceutical Secures First Southeast Asian Approval for VAZKEPA® (Icosapent Ethyl) in Singapore

Lotus Pharmaceutical Secures First Southeast Asian Approval for VAZKEPA® (Icosapent Ethyl) in Singapore